(Q37622873)

21 August 2017

1 reference

title

Mantle cell lymphoma: state-of-the-art management and future perspective (English)

1 reference

21 August 2017

1 reference

4

Martin Dreyling

1 reference

21 August 2017

2

Michael Unterhalt

1 reference

21 August 2017

Oliver Weigert

1

1 reference

21 August 2017

Wolfgang Hiddemann

series ordinal

3

1 reference

21 August 2017

publication date

1 December 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

50

1 reference

21 August 2017

issue

12

1 reference

21 August 2017

page(s)

1937-1950

1 reference

Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Mantle cell lymphoma: established therapeutic options and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Current treatment approaches for mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Central nervous system involvement in patients with mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Central nervous system involvement in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Limited-stage mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Patterns of survival in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

The role of fludarabine in the treatment of follicular and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

The role of low-dose total body irradiation in treatment of non-Hodgkin's lymphoma: a new look at an old method.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Cyclooxygenase-2 inhibitors in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Radioimmunotherapy for Non-Hodgkin's Lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

The ubiquitin-proteasome proteolytic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

The proteasome: a suitable antineoplastic target

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentr

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Increased MDM2 expression is associated with inferior survival in mantle cell lymphoma, but not related to the MDM2 SNP309

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin’s lymphomas: a single center experience on 18 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903288514

10.3109/10428190903288514

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference